Sabio

Singapore Advanced Biologics Pte. Ltd. (SABio) was established in 2010 to supply biologics to the research community in Singapore and the surrounding region. The company was founded by two professors from Duke-NUS, Mariano Garcia-Blanco and Subhash Vasudevan. In 2011, SABio secured investments from Bioveda Capital and SingHealth.

SABio operates as a manufacturer and seller in the research and development market, focusing on producing quality biologics. Its business model revolves around the research, development, and production of these materials for scientific researchers. The company's clients are primarily within the research community, who require timely access to specialized biological products for their work. One of the company's operational strengths is its ability to deliver ready-made catalogue antibodies to research facilities in Singapore rapidly, sometimes on the same or next business day.

The company's product and service portfolio is centered on biologics. This includes the production of siRNA, RNA oligos, custom siRNA libraries, synthetic peptides, and both ready-made and custom-produced antibodies. These products serve as essential tools for researchers engaged in various fields of biological and medical science. According to company information records, the firm is currently in liquidation as of June 2024.

Keywords: biologics manufacturing, research and development, life sciences, RNA oligos, custom antibodies, synthetic peptides, siRNA libraries, antibody production, molecular biology reagents, cell biology reagents, Singapore biotech, Duke-NUS, scientific research tools, laboratory supplies, protein synthesis, gene silencing, biotech startup, life science research, biomedical research, drug discovery